A recent study in probable iRBD patients illustrated that a reduced ratio of phosphorylated tau to total tau was associated with phenoconversion to a synucleinopathy disease at a 5-year follow-up highlighting the potential use of fluid biomarkers to track progression in iRBD [31••]. The gene discussed is MAPT; the disease is synucleinopathy.